Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTREM (nangibotide) in patients with septic shock
2016-005032-14Phase 2Completed
- Sponsor
- Inotrem
- Start
- Mar 2017
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of nangibotide in septic shock, bacterial disease and mycoses (4 arms), sponsored by Inotrem. Primary endpoint: Safety and tolerability parameters. Started Mar 2017; status: completed.
02
Drugs
nangibotide
03
Conditions
septic shockbacterial diseasemycoses
Beyond the preview
Go deeper on 2016-005032-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-005032-14.